Lecanemab (Dutch Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lecanemab" in Dutch language version.

refsWebsite

Global rank Dutch rank

5web.archive.org

1^st place

1^st place

2theguardian.com

12^th place

24^th place

4^th place

12^th place

2^nd place

8^th place

906^th place

5^th place

low place

low place

7^th place

27^th place

1clinicaltrials.gov

5,225^th place

2,839^th place

68^th place

39^th place

biogen.com

investors.biogen.com

(en) Lecanemab Confirmatory Phase 3 Clarity Ad Study Met Primary Endpoint, Showing Highly Statistically Significant Reduction of Clinical Decline in Large Global Clinical Study of 1,795 Participants With Early Alzheimer's Disease. Biogen (28 september 2022). Gearchiveerd op 1 december 2022. Geraadpleegd op 30 november 2022.

clinicaltrials.gov

(en) A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (Clarity AD). ClinicalTrials.gov (11 juli 2022). Gearchiveerd op 30 november 2022. Geraadpleegd op 30 november 2022.

doi.org

(en) (2014). Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimer's Research & Therapy 6 (2): 16. PMID 25031633. PMC 4054967. DOI: 10.1186/alzrt246.
(en) (March 2018). The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death. Journal of Neuroinflammation 15 (1): 98. PMID 29592816. PMC 5875007. DOI: 10.1186/s12974-018-1134-4.

europa.eu

ema.europa.eu

[https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-leqembi-lecanemab_en.pdf Refusal of the marketing authorisation for Leqembi (lecanemab)]

nih.gov

ncbi.nlm.nih.gov

(en) (2014). Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimer's Research & Therapy 6 (2): 16. PMID 25031633. PMC 4054967. DOI: 10.1186/alzrt246.
(en) (March 2018). The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death. Journal of Neuroinflammation 15 (1): 98. PMID 29592816. PMC 5875007. DOI: 10.1186/s12974-018-1134-4.

nytimes.com

(en) Alzheimer's Drug Slows Cognitive Decline in Key Study. New York Times (27 september 2022). Gearchiveerd op 19 november 2022. Geraadpleegd op 20 november 2022.

theguardian.com

(en) Success of experimental Alzheimer's drug hailed as 'historic moment'. The Guardian (28 september 2022). Gearchiveerd op 28 september 2022.
(en) 'This looks like the real deal': Are we inching closer to a treatment for Alzheimer's?. TheGuardian.com (30 november 2022). Gearchiveerd op 15 april 2023.

volkskrant.nl

Keulemans, Maarten, Alzheimermedicijn werkt matig, experts toch verrukt om ‘historisch moment’. de Volkskrant (30 november 2022). Geraadpleegd op 30 november 2022.

web.archive.org

(en) Success of experimental Alzheimer's drug hailed as 'historic moment'. The Guardian (28 september 2022). Gearchiveerd op 28 september 2022.
(en) Lecanemab Confirmatory Phase 3 Clarity Ad Study Met Primary Endpoint, Showing Highly Statistically Significant Reduction of Clinical Decline in Large Global Clinical Study of 1,795 Participants With Early Alzheimer's Disease. Biogen (28 september 2022). Gearchiveerd op 1 december 2022. Geraadpleegd op 30 november 2022.
(en) Alzheimer's Drug Slows Cognitive Decline in Key Study. New York Times (27 september 2022). Gearchiveerd op 19 november 2022. Geraadpleegd op 20 november 2022.
(en) A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (Clarity AD). ClinicalTrials.gov (11 juli 2022). Gearchiveerd op 30 november 2022. Geraadpleegd op 30 november 2022.
(en) 'This looks like the real deal': Are we inching closer to a treatment for Alzheimer's?. TheGuardian.com (30 november 2022). Gearchiveerd op 15 april 2023.